DK174044B1 - Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid....... - Google Patents

Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid....... Download PDF

Info

Publication number
DK174044B1
DK174044B1 DK198706809A DK680987A DK174044B1 DK 174044 B1 DK174044 B1 DK 174044B1 DK 198706809 A DK198706809 A DK 198706809A DK 680987 A DK680987 A DK 680987A DK 174044 B1 DK174044 B1 DK 174044B1
Authority
DK
Denmark
Prior art keywords
dna
csf
polypeptide
amino acid
ser
Prior art date
Application number
DK198706809A
Other languages
Danish (da)
English (en)
Other versions
DK680987D0 (da
DK680987A (da
Inventor
Kazuo Yamaguchi
Motoo Yamasaki
Masami Okabe
Tetsuro Kuga
Yoshinori Komatsu
Hiromasa Miyaji
Moriyuki Sato
Makoto Morimoto
Seiga Itoh
Yoshiharu Yokoo
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17961392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK174044(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of DK680987D0 publication Critical patent/DK680987D0/da
Publication of DK680987A publication Critical patent/DK680987A/da
Application granted granted Critical
Publication of DK174044B1 publication Critical patent/DK174044B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK198706809A 1986-12-23 1987-12-22 Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid....... DK174044B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP30679986 1986-12-23
JP30679986 1986-12-23

Publications (3)

Publication Number Publication Date
DK680987D0 DK680987D0 (da) 1987-12-22
DK680987A DK680987A (da) 1988-06-24
DK174044B1 true DK174044B1 (da) 2002-05-06

Family

ID=17961392

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198706809A DK174044B1 (da) 1986-12-23 1987-12-22 Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid.......

Country Status (10)

Country Link
EP (1) EP0272703B2 (no)
JP (1) JPH068317B2 (no)
KR (1) KR960016560B1 (no)
CA (1) CA1341522C (no)
DE (1) DE3786767T3 (no)
DK (1) DK174044B1 (no)
ES (1) ES2059354T5 (no)
HK (1) HK164195A (no)
NO (1) NO176799C (no)
PT (1) PT86465B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
US5298603A (en) * 1985-12-21 1994-03-29 Hoechst Aktiengesellschaft GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) * 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
US7119182B1 (en) 1991-02-19 2006-10-10 The Regents Of The University Of California Recombinant thrombin receptor and related pharmaceuticals
US5688768A (en) * 1991-02-19 1997-11-18 Cor Therapeutics, Inc. Recombinant thrombin receptor and related pharmaceuticals
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
PT744409E (pt) 1994-02-23 2008-11-03 Kyowa Hakko Kogyo Kk Acelerador do crescimento das plaquetas
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6100070A (en) * 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
DE19860801A1 (de) * 1998-12-30 2000-07-06 Rhein Biotech Proz & Prod Gmbh Rekombinanter Wachstumsfaktor mit der biologischen Aktivität eines G-CSF (Granulocyte Colony Stimulating Factor)
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
EP1317537B1 (en) 2000-09-08 2006-12-20 Massachusetts Institute Of Technology G-csf analog compositions and methods
MXPA03007002A (es) 2001-02-06 2003-11-18 Merck Patent Gmbh Factor estimulante de colonia de granulocitos (g-csf) modificado con inmunogenicidad reducida.
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
EP1425304B9 (en) 2001-07-11 2010-09-08 Maxygen, Inc. G-csf conjugates
AU2003210052A1 (en) 2002-03-20 2003-09-29 Biopolymed Inc. Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue
AU2003261723A1 (en) 2002-08-27 2004-03-19 Takeda Chemical Industries, Ltd. Cxcr4 antagonist and use thereof
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
JP4607010B2 (ja) 2003-02-28 2011-01-05 中外製薬株式会社 タンパク質含有安定化製剤
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20060153799A1 (en) 2004-11-05 2006-07-13 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
CN101193658B (zh) 2005-06-01 2011-08-31 马克西根控股公司 聚乙二醇化g-csf多肽及其产生方法
US8455450B2 (en) 2006-12-21 2013-06-04 Biokine Therapeutics Ltd. Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof
EP2185689A2 (en) 2007-08-09 2010-05-19 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
WO2009046015A2 (en) 2007-09-30 2009-04-09 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US9155780B2 (en) 2009-02-11 2015-10-13 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
ES2462517T3 (es) 2009-06-14 2014-05-23 Biokine Therapeutics Ltd. Terapia con péptidos para aumentar los niveles de plaquetas
JP5657698B2 (ja) 2010-01-19 2015-01-21 ハンミ サイエンス カンパニー リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅｃｏ．，Ｌｔｄ． 持続型顆粒球コロニー刺激因子結合体の液剤
JP5840148B2 (ja) 2010-03-04 2016-01-06 フェニックス インク． 変性させることなく可溶性組換えインターフェロンタンパク質を産生する方法
CA2794740C (en) 2010-04-01 2019-12-31 Pfenex Inc. Methods for g-csf production in a pseudomonas host cell
EP2841084B1 (en) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
CA3014530A1 (en) 2016-02-23 2017-08-31 Biolinerx Ltd. Methods of treating acute myeloid leukemia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4869987A (no) 1971-12-27 1973-09-22
JPS58110600A (ja) 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
DE3680613D1 (de) * 1985-02-08 1991-09-05 Chugai Pharmaceutical Co Ltd Menschlicher granuloxcyt-kolonie-stimulierungsfaktor.
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
ATE67517T1 (de) * 1985-09-30 1991-10-15 Chugai Pharmaceutical Co Ltd Menschlicher granulozyten-colony stimulierender faktor.
EP0256843A1 (en) 1986-08-11 1988-02-24 Cetus Corporation Expression of g-csf and muteins thereof and their use
JP2581110B2 (ja) * 1987-10-26 1997-02-12 いすゞ自動車株式会社 パティキュレートトラップの再燃焼装置

Also Published As

Publication number Publication date
CA1341522C (en) 2007-03-13
KR960016560B1 (ko) 1996-12-14
NO875378D0 (no) 1987-12-22
HK164195A (en) 1995-10-27
ES2059354T5 (es) 1998-03-16
NO176799C (no) 1995-05-31
PT86465A (en) 1988-01-01
DE3786767T2 (de) 1994-01-13
EP0272703B1 (en) 1993-07-28
KR880007734A (ko) 1988-08-29
NO176799B (no) 1995-02-20
ES2059354T3 (es) 1994-11-16
EP0272703A1 (en) 1988-06-29
EP0272703B2 (en) 1997-10-15
JPS63267292A (ja) 1988-11-04
DK680987D0 (da) 1987-12-22
PT86465B (pt) 1990-11-20
NO875378L (no) 1988-06-24
DE3786767T3 (de) 1998-04-16
DE3786767D1 (de) 1993-09-02
JPH068317B2 (ja) 1994-02-02
DK680987A (da) 1988-06-24

Similar Documents

Publication Publication Date Title
DK174044B1 (da) Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid.......
Amann et al. Tightly regulated tac promoter vectors useful for the expression of unfused and fused proteins in Escherichia coli
US4678751A (en) Hybrid human leukocyte interferons
CA2070503C (en) A-c-b proinsulin, method of manufacturing and using same, and intermediates in insulin production
US4456748A (en) Hybrid human leukocyte interferons
US4897348A (en) Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof
GB2137208A (en) The use of the gal1 promoter
EP0188920B1 (en) Interleukin 1 and its derivative
US5994518A (en) Method of producing a polypeptide having human granulocyte colony stimulating factor activity
HU202287B (en) Process for producing human immune interferon
GB2090258A (en) Hybrid leukocyte interferon
IE64441B1 (en) Dna sequences recombinant dna molecules and processes for producing swine growth hormone-like polypeptides
EP1837346A2 (en) Method for purifying granulocyte-colony stimulating factor
EP0232107A2 (en) Human lymphotoxin polypeptide derivative
WO1985001067A1 (en) Recombinant materials and methods for producing human connective tissue-activating peptide-iii and analogs thereof
GB2143535A (en) Improved plasmid vector and use thereof
JP2548204B2 (ja) 新生理活性ポリペプチド
HU214698B (hu) Eljárás rekombináns deszulfátó-hirudin HV-1 peptidek előállítására
NO315003B1 (no) Fremgangsmåte for fremstilling av polypeptid samt DNA-sekvens som koder fordette
JP2766798B2 (ja) 新規ポリペプチド
JP2673099B2 (ja) 新規ポリペプチド
JP2628961B2 (ja) 新規ポリペプチド
JPS61291598A (ja) 魚類カルシトニン誘導体及びその製造方法
JPS6384500A (ja) ヒト２０ｋ成長ホルモンの製造方法
JPH051800B2 (no)

Legal Events

Date Code Title Description
ATS Application withdrawn
PUP Patent expired